摘要
目的观察双环醇联合阿德福韦酯治疗慢性乙型肝炎的临床疗效。方法选择慢性乙型肝炎患者60例,随机分为对照组和治疗组,每组30例。对照组患者予以口服阿德福韦酯10mg.次-1,1次.d-1;治疗组在对照组治疗的基础上加服双环醇25mg,3次.d-1,2组均连续用药6个月,比较2组治疗效果。结果治疗后2组患者ALT和AST水平较治疗前均明显降低(P<0.05),但治疗后2组比较差异均无统计学意义(P>0.05);停药3个月后治疗组ALT和AST水平的改善显著优于对照组(P<0.05);治疗6个月和停药3个月治疗组患者的HBeAg阴转率、HBV-DNA阴转率以及HBeAb阳转率均明显优于对照组(P<0.05)。结论双环醇联合阿德福韦酯具有较好的保肝、降低血清转氨酶作用,在抗病毒方面也具明显优势。
Objective To observe the clinical effect of bicyclol combined with adefovir dipivoxil on chronic hepatitis B. Methods Sixty patients with chronic hepatitis B were treated with oral adefovir dipivoxil 10 mg once daily （control group,n= 30） or in combination with bicyclol 25 mg 3 times per day （treatment group,n= 30） for 6 months. The clinical effects were compared between the two groups. Results After treatment,the levels of alanine aminotransferase （ALT） and as- partate aminotransferase （AST） obviously decreased （P〈0. 05）, but no significant differences were observed between the two groups （P〉0. 05）. Compared with control group, levels of ALT and AST were significantly improved in treatment group after drug withdrawal for 3 months （P〈0.05）. Furthermore, HBeAg negative conversion rate, HBV-DNA negative conversion rate and HBeAb positive conversion rate in treatment group were better than those in control group after treatment for 6 months and drug withdrawal for 3 months （P〈0.05）. Conclusion Bicyclol combined with adefovir dipivoxil has hepatoprotective and antivirus activities and can decrease se- rum transaminases levels.
出处
《实用临床医学（江西）》
CAS
2012年第3期19-21,共3页
Practical Clinical Medicine
